Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Interest Expenses (2025)

Crescent Biopharma (CBIO) has disclosed Interest Expenses for 1 consecutive years, with $1.1 million as the latest value for Q2 2025.

  • For Q2 2025, Interest Expenses changed N/A year-over-year to $1.1 million; the TTM value through Mar 2026 reached $1.1 million, down 3.51%, while the annual FY2025 figure was $2.2 million, N/A changed from the prior year.
  • Interest Expenses hit $1.1 million in Q2 2025 for Crescent Biopharma, down from $1.1 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.1 million in Q1 2025 and bottomed at $1.1 million in Q2 2025.